Peptide-Major Histocompatibility Complex (pMHC) multimers have become one of the most widely used tools to measure antigen-specific T cell responses in humans. With the aim to understand the requirements for pMHC-based personalized immunomonitoring -in which individuals expressing subtypes of the commonly studied HLA alleles are encountered -we assessed how the ability to detect antigen-specific T cells for a given peptide is affected by micropolymorphic differences between HLA subtypes. These data provide the first demonstration of the strong effect of minor sequence variation on pMHC-based personalized immunomonitoring, and provide tools to prevent this issue for common variants within the HLA-A*02 allele group.
Introduction
In 1996, Altman and colleagues described how multimers of peptide-Major Histocompatibility Complexes (pMHC) coupled to fluorochromes can be utilized to monitor antigen-specific CD8 + T cells by flow cytometry. Since this first description, pMHC multimer-based immunomonitoring has become a very widely used technique to understand spontaneous and therapy-induced T cell reactivity in different fields, as illustrated by the > 3,000 citations to the original work (1) . In addition to the use of pMHC multimers for the quantification of antigen-specific T cell responses (2) . These tools have also been utilized for the isolation of antigen-specific T cells for both research purposes and adoptive cell therapy (3) and to describe the composition of the naïve T cell compartment (4, 5) .
Traditionally, MHC-based immunomonitoring projects have focused on analyses of T cell reactivity towards a small number of epitopes, restricted by a few Human Leukocyte Antigen (HLA) alleles that are present at high frequency within the Caucasian population.
To illustrate this bias, more than 65% of melanoma-associated antigens described in literature is restricted by the HLA-A*02 allele (6) , even though this allele is only one of the many HLA-A alleles that are present. Notably, in non-Caucasian populations, the HLA-A*02:01 subtype (by far the most frequent subtype in Caucasians) is present in only a minor fraction of HLA-A*02-positive individuals (7) .
The variation between the subtypes of specific HLA alleles (traditionally referred to as '4-digit subtypes') maps to a small number of sequence differences within the a1 or a2 domains of the MHC heavy chain, which together form the peptide-binding groove.
Depending on their location, these sequence differences may influence T cell recognition by modifying the peptide binding properties of the MHC (8) or altering the TCR exposed surface, or may be without effect.
Here we have assessed the extent to which the ability to correctly measure antigenspecific T cell responses against a given epitope by pMHC multimer technology is influenced by such micropolymorphic differences between HLA subtypes. Our results demonstrate that minor variations between HLA subtypes greatly affect the ability to detect antigen-specific CD8 + T cell responses in both model systems and clinical samples.
Furthermore, in many cases, this lack of T cell detection reflects altered TCR interaction of the pMHC complex, rather than impaired MHC binding of epitopes, and can therefore not be predicted by peptide-MHC binding assays. Collectively, these data indicate that the generation of pMHC-based monitoring technology for large sets of HLA subtypes, as performed here for HLA-A*02, will be of importance for the development of personalized pMHC-based immunomonitoring.
Materials and methods

HLA-A*02 subtypes.
Amino acid sequences of the HLA-A*02 alleles were obtained from the IMGT/HLA- Cartoon representations of the CMV NLV specific T cell receptor (RA14) in complex with the CMV NLV -HLA-A*02:01 complex (10) (PDB code 3GSN) were drawn using Pymol software.
pMHC-complex ELISA and peptide-MHC binding predictions.
A streptavidin-based sandwich ELISA was used to assess the ability of peptides to stabilize the HLA-A*02:01, HLA-A*02:02, HLA-A*02:05, HLA-A*02:07, HLA-A*02:11, HLA-A*02:71, and HLA-A*02:77 subtypes, as described (11), using the peliscreen HLA class I ELISA kit (Sanquin). In brief, after UV-mediated peptide exchange in the presence of indicated peptides, biotinylated HLA class I molecules were added to wells coated with streptavidin. HLA class I complexes bound to the well were quantified using an HRPconjugated anti-β2m antibody. Green-colored oxidation product was produced by adding ABTS as a substrate for HRP.
The following peptide sequences were submitted to the NetMHCpan server http:// 
Generation of pMHC complexes
Indicated virus-derived, melanoma-associated, and ultraviolet (UV) cleavable peptides were synthesized in-house as described previously (13) . Recombinant HLA-A*02 subtypespecific heavy chains and human m2m light chain were produced in Escherichia coli and isolated from inclusion bodies. MHC class I refolding reactions and purification by gelfiltration HPLC was performed as described previously (14) . HLA-A*02 subtypes were refolded in the presence of the following UV-sensitive peptides: KILGFVF-J-V, KMDI-J-VPLL, LLDSD-J-ERL, LTA-J-FLIFL and SVRD-J-LARL. MHC complexes loaded with the indicated peptides of interest were generated by UV-induced ligand exchange. In brief, pMHC complexes with UV-sensitive peptide (100 mg ml -1 ) were subjected to 366 nM UV light (Camag) for 1h at 4°C in the presence of rescue peptide (200 mM) (13, 15) .
Generation of pMHC-multimers
For each peptide, pMHC-multimers were generated using two different fluorescent streptavidin (SA) conjugates (Invitrogen) (16) . T cell clones were stained with dual color labelled pMHC multimers. Tumor Infiltrating Lymphocytes (TIL) were analysed by combinatorial pMHC multimer stainings, in which pMHC multimers loaded with 25 different peptides were utilized simultaneously in each staining reaction, with each pMHC combination encoded by a unique 2-color combination (17) . (18) .
Generation of CD8 T cell clones
To obtain bulk melanoma-associated antigen-specific T cell populations MART-1 ELA (ELAGIGILTV) and GnTV VLP (VLPDVFIRC) of an HLA-A*02:06 positive melanoma patient, tumor-infiltrating lymphocytes were first expanded using a 14-day rapid expansion protocol (REP) (19) . In brief, irradiated (40 gy) PBMC feeders of 3 different healthy donors were combined and taken in culture with TIL (ratio 20: 1, feeder: T cell) in the presence of anti-CD3 (OKT3, final concentration 30 ng/mL) and IL-2 (final concentration 3,000 IU/mL).
Half of the medium was replaced after 5 days, cultures were split 1:1 on day 7 and when needed afterwards. After 12-14 days, T cells were frozen. MART-1 ELA and GnTV VLP -specific T cell populations were isolated from expanded TIL, by sorting of live single CD8 + T cells stained with phycoerythrin/allophycocyanin (PE/APC)-labelled pMHC-multimers. Obtained MART-1 ELA and GnTV VLP cell populations were further expanded, using the above-described rapid expansion protocol.
TIL were stored in liquid nitrogen and were thawed one day prior to analysis. As a standard, cell numbers were determined by trypan blue staining, with an average recovery of 93%.
HLA haplotyping
Four-digit resolution HLA haplotyping was performed by the LUMC, Leiden, The
Netherlands. Typing was performed according to the manufacturer's protocol, using
SBTexcellerator HLA-A, -B, -C typing kits (GENDX).
T cell staining
For pMHC multimer staining of CD8 + T cell clones, 1μL PE-pMHC and 2μL APC-pMHCmultimers were used to stain cells in a 15 min incubation at 37°C. Subsequently, cells
were stained with a-CD8-FITC (BD-Biosciences) and near-IR live/dead stain (Invitrogen) for 30 min on ice and washed twice with FACS buffer. Background signal was determined by staining with pMHC multimers loaded with a control peptide, HIV SLY (SLYNTVATL).
For pMHC combinatorial encoding, each peptide-MHC complex was coupled to a unique combination of 2 fluorochromes (fluorochrome concentrations described in (16)).
The melanoma associated epitope panel consisting of 145 different peptides has been described previously (16) .
Detection of antigen-specific T cells
Antigen-specific T cells were detected using an LSR-II flow cytometer (Becton Dickinson) with FacsDiva software (Becton Dickinson). To identify antigen-specific T cells when staining CD8 + T cell clones, the following gating strategy was used. All FCS files are available for scientific research purposes upon request.
Results
Peptide exchange technology for a series of HLA-A*02 subtypes.
In 
Influence of HLA subtype variation on MHC-based high-throughput immunomonitoring
In the above analyses, pMHC multimers were generated using HLA A*02 subtypes for which these 10 epitopes were originally not identified. We next wished to assess whether a set of HLA-A*02:01 multimers loaded with previously described epitopes for (Figure 4) . Furthermore, the T cell response specific for the GnTV VLP antigen was missed entirely when using HLA-A*02:01 pMHC-multimers, even though this peptide constitutes a bona fide HLA-A*02:01 restricted epitope (25) .
To also investigate the reactivity of these HLA-A*02:06 restricted T cell populations with the other HLA-A*02 subtypes, the GnTV VLP and MART-1 ELA specific T cell populations present in this TIL product were isolated using HLA-A*02:06 restricted pMHC multimers.
Subsequently, both T cell populations were stained with the panel of HLA-A*02 subtype multimers (representative dot plots shown in Figure 5a ). High intensity staining (MFI: 
Discussion
Here we demonstrate that micropolymorphic variation between HLA subtypes can greatly influence the ability to describe human antigen-specific CD8 + T cell responses by pMHCmultimer staining. We have analyzed this issue for 88 situations in which antigen-specific Based on this earlier work on target cell recognition, and based on the observation that the peptides studied here were shown to bind to most of the HLA-A*02 subtype alleles (Figure 3 ), we consider it likely that altered TCR recognition of pHLA subtype variants also forms the major factor preventing accurate T cell detection here. Furthermore, the observation that for polyclonal antigen-specific T cell populations, subtype-mismatched HLA multimers in some cases selectively fail to detect part of the antigen-specific T cell population (Figure 5b ), also provides evidence for altered TCR binding as a contributing mechanism. As such, it will not be feasible to prevent this issue by peptide-MHC binding studies.
The current data clearly demonstrate that human immunomonitoring requires highresolution matching between the HLA alleles of biological samples and the pMHC reagents used for monitoring. Pioneering work of Dausset, Bodmer and others resulted in the first descriptions of HLA antigens by serological typing (30) . Serological typing of the HLA haplotype is experimentally straightforward, and is still commonly used in clinical studies that utilize pMHC-based monitoring (31, 32) . Likewise, the use of low-resolution PCR for HLA haplotype analysis, as still frequently performed (33), does not provide information on the sequence variability that is here shown to be of major importance. In future clinical studies, this issue may be readily addressed by incorporation of high resolution PCR-based haplotyping. In addition, for the recently developed approaches that aim to obtain HLA haplotype information from whole exome/ RNAseq next generation (NGS) sequencing data it will also be important to ensure that high resolution is achieved (34) (35) (36) .
The HLA subtype tools developed here for HLA-A*02 should contribute to the development of the personalized immunomonitoring that is made possible by next generation sequencing of pathogens and tumors. As a first example, next generation sequencing of viral quasispecies will make it feasible to follow the dynamic relationship between the T cell repertoire and the viral quasispecies for viruses such as HCV and HIV. As a second example, human tumors contain large numbers of mutations that lead to altered (non-self) peptide sequences that are unique to each patient. Because these sequences
have not been encountered during T cell development (i.e. are 'foreign'), it may be speculated that T cells recognizing these mutated epitopes are of particular importance in (therapy-induced) T cell-mediated tumor regression (37) . Recent work by Rosenberg (38) and us (39) has demonstrated how cancer exome sequencing data can be used to reveal T cell responses against patient-specific neo-antigens in humans, and how such responses can be influenced by immunotherapy (39) . The development of pMHC based monitoring technology for large sets of HLA subtypes will be of substantial importance for such 
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